Intervention Review

You have full text access to this OnlineOpen article

Abacavir-based triple nucleoside regimens for maintenance therapy in patients with HIV

  1. Mario Cruciani1,*,
  2. Carlo Mengoli2,
  3. Giovanni Serpelloni3,
  4. Saverio G Parisi2,
  5. Marina Malena4,
  6. Oliviero Bosco4

Editorial Group: Cochrane HIV/AIDS Group

Published Online: 5 JUN 2013

Assessed as up-to-date: 10 JUL 2012

DOI: 10.1002/14651858.CD008270.pub2

How to Cite

Cruciani M, Mengoli C, Serpelloni G, Parisi SG, Malena M, Bosco O. Abacavir-based triple nucleoside regimens for maintenance therapy in patients with HIV. Cochrane Database of Systematic Reviews 2013, Issue 6. Art. No.: CD008270. DOI: 10.1002/14651858.CD008270.pub2.

Author Information

  1. 1

    ULSS 20 Verona, Center of Community Medicine and Infectious Diseases Service, Verona, Italy

  2. 2

    Università di Padova, Department of Histology, Microbiology and Medical Biotechnology, PADOVA, Italy

  3. 3

    ULSS 20 Verona, Dipartimento delle Dipendenze, 37135 Verona, Italy

  4. 4

    ULSS 20 Verona, Center of Community Medicine, 37135 Verona, Italy

*Mario Cruciani, Center of Community Medicine and Infectious Diseases Service, ULSS 20 Verona, Via Germania, 20, Verona, 37135, Italy. crucianimario@virgilio.it.

Publication History

  1. Publication Status: New
  2. Published Online: 5 JUN 2013

SEARCH

[Figure 1]
Figure 1. Flow diagram.
[Figure 2]
Figure 2. Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies.
[Figure 3]
Figure 3. Risk of bias summary: review authors' judgements about each risk of bias item for each included study.
[Figure 4]
Figure 4. Forest plot of comparison: 1 Abacavir vs PI continuation or NNRTI, outcome: 1.1 Failure (overall).
[Figure 5]
Figure 5. Forest plot of comparison: 1 Abacavir vs PI continuation or NNRTI, outcome: 1.2 Discontinuation for adverse events.
[Figure 6]
Figure 6. Forest plot of comparison: 1 Abacavir vs PI continuation or NNRTI, outcome: 1.3 Virologic failure.
[Figure 7]
Figure 7. Forest plot of comparison: 1 Abacavir vs PI continuation or NNRTI, outcome: 1.4 Death.
[Figure 8]
Figure 8. Forest plot of comparison: 1 Abacavir vs PI continuation or NNRTI, outcome: 1.5 Death & AIDS related events.
[Figure 9]
Figure 9. Forest plot of comparison: 1 Abacavir vs PI continuation or NNRTI, outcome: 1.6 Any Adverse Events.
[Figure 10]
Figure 10. Forest plot of comparison: 1 Abacavir vs PI continuation or NNRTI, outcome: 1.7 Rate of patients with Viral Load < 50 cp/ml.
[Figure 11]
Figure 11. Forest plot of comparison: 2 ABC vs NNRTI, outcome: 2.1 Failure (overall).
[Figure 12]
Figure 12. Forest plot of comparison: 2 ABC vs NNRTI, outcome: 2.2 Discontinuation for Adverse Events.
[Figure 13]
Figure 13. Forest plot of comparison: 2 ABC vs NNRTI, outcome: 2.3 Virologic failure.
[Analysis 1.1]
Analysis 1.1. Comparison 1 Abacavir vs PI continuation or NNRTI, Outcome 1 Failure (overall).
[Analysis 1.2]
Analysis 1.2. Comparison 1 Abacavir vs PI continuation or NNRTI, Outcome 2 Discontinuation for adverse events.
[Analysis 1.3]
Analysis 1.3. Comparison 1 Abacavir vs PI continuation or NNRTI, Outcome 3 Virologic failure.
[Analysis 1.4]
Analysis 1.4. Comparison 1 Abacavir vs PI continuation or NNRTI, Outcome 4 Death.
[Analysis 1.5]
Analysis 1.5. Comparison 1 Abacavir vs PI continuation or NNRTI, Outcome 5 Death & AIDS related events.
[Analysis 1.6]
Analysis 1.6. Comparison 1 Abacavir vs PI continuation or NNRTI, Outcome 6 Any Adverse Events.
[Analysis 1.7]
Analysis 1.7. Comparison 1 Abacavir vs PI continuation or NNRTI, Outcome 7 Rate of patients with Viral Load < 50 cp/ml.
[Analysis 2.1]
Analysis 2.1. Comparison 2 ABC vs NNRTI, Outcome 1 Failure (overall).
[Analysis 2.2]
Analysis 2.2. Comparison 2 ABC vs NNRTI, Outcome 2 Discontinuation for Adverse Events.
[Analysis 2.3]
Analysis 2.3. Comparison 2 ABC vs NNRTI, Outcome 3 Virologic failure.